F-1/A: Tianan Technology Group Files F-1/A for 10M Share Resale

Tianan Technology Group Ltd. has filed an amendment to its registration statement for the resale of 10M ordinary shares by existing shareholders.

Summary

• Tianan Technology Group Ltd. is a BVI holding company operating in China through its subsidiary, Shanghai Qige Power Technology Co., Ltd.
• The company focuses on graphene-based health therapy products, including saunas, blankets, pillows, and knee pads.
• Revenue for the fiscal year ended December 31, 2025, was $734,893, a 58.8% decrease from $1,783,130 in 2024.
• The company reported a net loss of $89,931 for 2025, compared to a net income of $454,590 in 2024.
• The filing covers the resale of 10,000,000 ordinary shares previously issued in a private placement at $3.70 per share.
• The company does not receive any proceeds from the resale of these shares.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a high-risk filing due to the significant decline in financial performance, working capital deficit, and the inherent risks of operating as a China-based entity listed in the U.S.

Positives

• The company has established a diversified product line in the growing graphene health therapy market.
• The company has implemented a dual-track settlement mechanism to balance cash flow and customer loyalty.
• The company has successfully secured strategic cooperation agreements with suppliers like Xiwang New Materials Technology Co., Ltd.

Negatives

• Revenue declined significantly by 58.8% year-over-year in 2025.
• The company swung from a net profit of $454,590 in 2024 to a net loss of $89,931 in 2025.
• The company has a working capital deficit of $71,775 as of December 31, 2025.
• The company lacks D&O insurance and has identified material weaknesses in its internal controls over financial reporting.
• The company is dependent on a limited number of customers, with significant revenue concentration risks.

Risks

• Significant operational and legal risks associated with conducting business in China, including potential government intervention.
• Uncertainty regarding the ability to maintain a listing on a U.S. exchange due to potential regulatory or audit inspection issues.
• The company is an emerging growth company and a foreign private issuer, which may limit investor protections.
• The company's stock is considered a 'penny stock,' which may limit marketability and liquidity.
• The company has no current market for its shares and no guarantee that a trading market will develop.
• The company is dependent on the continued service of its founder and CEO, Mr. Heng Fei Yang.

Future Outlook

The company intends to continue its focus on graphene-based health therapy products, expand its sales and distribution network, and pursue potential strategic collaborations or acquisitions. It does not anticipate paying dividends in the foreseeable future.

Management Comments

• Management believes the company is well-positioned to capitalize on the growing graphene industry within the health therapy sector.
• Management notes that the company's success depends on its ability to attract, incentivize, and retain talented professionals.

Industry Context

StockSavvy.ai notes that the company operates in the highly competitive and rapidly evolving graphene materials and health therapy sector in China, which is subject to significant regulatory oversight and economic policy shifts.

Comparison to Industry Standards

• The company faces competition from established players like Haydale Graphene Industries PLC and various Chinese competitors.
• The company's reliance on third-party suppliers for product manufacturing is common in the industry but presents supply chain risks.

Corporate Governance

Related Party Transactions

• The company received loan proceeds from its CEO, Mr. Heng Fei Yang, totaling $71,000 in 2025.
• The company had an outstanding loan balance of $537,724 to its CEO as of December 31, 2025.

Stakeholder Impact

• Shareholders face dilution risks and potential volatility due to the nature of the offering and the company's financial condition.
• Employees may be impacted by the company's cost-cutting measures and the need for improved internal controls.

Next Steps

• Seek quotation of ordinary shares on the OTC Markets.
• Continue to implement remedial measures for internal control weaknesses.
• Pursue potential financing initiatives to support operations.

Key Dates

Recommendation

The company's deteriorating financial performance, working capital deficit, and significant regulatory and operational risks make it a high-risk investment that does not meet the criteria for a stable or growth-oriented portfolio.

Keywords

Tianan Technology Group, Graphene, Health Therapy, F-1/A, China, Resale, Ordinary Shares